Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma
Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.
Authors
- Marie-Noëlle Kronig (ORCID: https://orcid.org/0009-0009-4988-4664)
- Thomas Pabst (ORCID: https://orcid.org/0000-0003-1493-806X)
- Alexander D. Heini (ORCID: https://orcid.org/0000-0002-2679-975X)
- Michael Daskalakis (ORCID: https://orcid.org/0000-0002-8138-0505)
- Ulrike Bacher (ORCID: https://orcid.org/0000-0001-8771-947X)
- François Volery
- Yara Banz
- Daniel Siegrist
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1159/000541256
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Inselspital, Universitätsspital Bern